Get the Stockscreener App
0.5201
5.50%
-0.0276
Cosmos Health Inc stock is traded at $0.5201, with a volume of 125.22K.
It is down -5.50% in the last 24 hours and down -28.42% over the past month.
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
See More
Previous Close:
$0.5477
Open:
$0.5413
24h Volume:
125.22K
Relative Volume:
0.31
Market Cap:
$12.74M
Revenue:
$56.04M
Net Income/Loss:
$-20.39M
P/E Ratio:
-0.2131
EPS:
-2.44
Net Cash Flow:
$-6.84M
1W Performance:
-8.31%
1M Performance:
-28.42%
6M Performance:
-54.19%
1Y Performance:
-34.11%
1-Day Range:
$0.5175
$0.5597
1-Week Range:
$0.5101
$0.6299
52-Week Range:
$0.4677
$1.58
Cosmos Health Inc Stock (COSM) Company Profile
Name
Cosmos Health Inc
Sector
Industry
Phone
312-536-3102
Address
5 AGIOU GEORGIOU, PILEA, THESSALONIKI
Compare COSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COSM
Cosmos Health Inc
|
0.5175 | 12.74M | 56.04M | -20.39M | -6.84M | -2.44 |
|
MCK
Mckesson Corporation
|
644.55 | 80.76B | 344.58B | 2.83B | 1.63B | 21.84 |
|
COR
Cencora Inc
|
255.72 | 49.62B | 303.19B | 1.40B | -638.10M | 7.03 |
|
CAH
Cardinal Health Inc
|
130.76 | 31.83B | 222.16B | 1.31B | -486.00M | 5.36 |
|
HSIC
Henry Schein Inc
|
72.44 | 9.32B | 12.50B | 314.00M | 421.00M | 2.44 |
|
PDCO
Patterson Companies Inc
|
31.18 | 2.74B | 6.55B | 155.22M | -823.13M | 1.71 |
Cosmos Health Inc Stock (COSM) Latest News
Cosmos Health Actively Exploring Spinoff of R&D Division into a Publicly Listed Standalone Biotech Company - ACCESS Newswire
Cosmos Health expands distribution of Avian Influenza kits - MSN
Cosmos Holdings Inc. Changes its Name to Cosmos Health Inc. and Announces a 1-For-25 Reverse Stock Split - ACCESS Newswire
Cosmos Health Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates - ACCESS Newswire
Cosmos Health CEO Grigorios Siokas acquires $200,000 in stock By Investing.com - Investing.com Canada
Cosmos Health CEO Grigorios Siokas acquires $200,000 in stock - Investing.com India
Cosmos Health CEO Acquires Shares Through Debt Exchange Agreement - TradingView
Cosmos Health postpones securities offering By Investing.com - Investing.com South Africa
Cosmos Health postpones securities offering - Investing.com India
Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1 - ACCESS Newswire
Strategic Shift: Cosmos Health Postpones Capital Raise, Prioritizes Annual Report - StockTitan
Cosmos Health Inc. (NASDAQ:COSM) Short Interest Down 39.7% in January - Defense World
Cosmos Health advances weight management device to clinical trials - MSN
Cosmos health CEO Grigorios Siokas acquires shares worth $29,999 - MSN
Cosmos Health Inc. (COSM) Expands IP Portfolio with AI-Driven Drug Repurposing Patents - Yahoo Finance
Cosmos Health files patents for cancer treatments By Investing.com - Investing.com Australia
Cosmos Health advances weight management device to clinical trials By Investing.com - Investing.com South Africa
Cosmos Health Enters Final Development Phase of CCX0722 Weight M - WICZ
Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market - ACCESS Newswire
Cosmos Health's Novel Weight Loss Device Enters Clinical Phase, Eyes Massive $142B Market Opportunity - StockTitan
Cosmos Health files patents for cancer treatments - Investing.com India
Cosmos Health Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies; $25 Billion+ Global Market - ACCESS Newswire
AI Breakthrough: Cosmos Health's Dual Cancer Patents Could Revolutionize $25B Treatment Market - StockTitan
Cosmos Health Appoints Dimitris Moraitis as Vice President of Strategy & Operations - citybiz
Cosmos Health Strengthens Management Team with the Appointment o - WICZ
Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations - ACCESS Newswire
Analyzing Ratios: Cosmos Health Inc (COSM)’s Financial Story Unveiled - The Dwinnex
Cosmos Health secures a 10-year contract with Provident - MSN
Cosmos Health Requests Appeal from the Nasdaq Stock Market - ACCESS Newswire
Cosmos Health Inc (NASDAQ: COSM) Up 32.86% From 52-Week Low; YTD Jumps 4.63% – Here’s What To Do Now - Marketing Sentinel
Cosmos Health secures a 10-year contract with Provident By Investing.com - Investing.com South Africa
Cosmos Health Pockets 10-Year Manufacturing Deal With Provident Pharmaceuticals - AOL
Cosmos Health's Cana Labs Signs 10-Year Manufacturing Deal With Provident Pharmaceuticals - Marketscreener.com
Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Backlog and Cash Flow Visibility - ACCESS Newswire
Major Pharma Contract: Cosmos Health to Manufacture Generic Versions of Lioresal, Zoloft - StockTitan
Cosmos Health Inc [COSM] Shares Fall Approximately -34.36% Over the Year - Knox Daily
Cosmos Health Receives $578,460 Initial Purchase Order from Al Rabwa International for Sky Premium Life Food Supplements in Qatar - ACCESS Newswire
Major Middle East Expansion: Cosmos Health Lands Exclusive $578K Qatar Distribution Contract - StockTitan
Cosmos Health Inc (COSM)’s stock price range in the last year - US Post News
Deeper Dive: Understanding Cosmos Health Inc (COSM) Through its Various Ratios - The Dwinnex
Cosmos Health Files Patent Application for Multiple Sclerosis Treatment -February 05, 2025 at 12:02 pm EST - Marketscreener.com
Cosmos Health Files New AI-Driven Patent Application for Multiple Sclerosis Treatment, Targeting $25 Billion+ Global Market - ACCESS Newswire
Revolutionary MS Treatment Patent: Cosmos Health's AI Platform Targets $26B Market - StockTitan
Cosmos Health Inc Stock (COSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cosmos Health Inc Stock (COSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Siokas Grigorios | Chief Executive Officer |
Jan 30 '25 |
Buy |
0.66 |
51,414 |
34,000 |
4,255,103 |
| Siokas Grigorios | Chief Executive Officer |
Jan 22 '25 |
Buy |
0.77 |
38,900 |
30,000 |
4,203,689 |
| Siokas Grigorios | Chief Executive Officer |
Jan 17 '25 |
Buy |
0.86 |
29,158 |
25,000 |
4,164,789 |
| Siokas Grigorios | Chief Executive Officer |
Jan 16 '25 |
Buy |
0.83 |
47,904 |
40,000 |
4,135,631 |
| Siokas Grigorios | Chief Executive Officer |
Jan 15 '25 |
Buy |
0.80 |
62,500 |
50,000 |
4,087,727 |
| Siokas Grigorios | Chief Executive Officer |
Jan 14 '25 |
Buy |
0.69 |
87,247 |
60,000 |
4,025,227 |
| Siokas Grigorios | Chief Executive Officer |
Jan 13 '25 |
Buy |
0.61 |
163,666 |
100,000 |
3,937,980 |
| Terzis Georgios | Chief Financial Officer |
Dec 20 '24 |
Buy |
0.58 |
85,778 |
50,000 |
727,263 |
| Siokas Grigorios | Chief Executive Officer |
Dec 20 '24 |
Buy |
0.58 |
257,334 |
150,000 |
3,774,314 |
0.23%
1.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):